Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019 Mar 5;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Timmis A, Gale CP, Flather M, et al. Cardiovascular disease statistics from the European atlas: inequalities between high- and middle-income member countries of the ESC. Eur Heart J Qual Care Clin Outcomes. 2018 Jan 1;4(1):1–3.
   PubMed Web of Science ®Google Scholar
• Alberts MJ, Bhatt DL, Mas JL, et al. Three-year follow-up and event rates in the international reduction of atherothrombosis for continued health registry. Eur Heart J. 2009 Oct;30(19):2318–2326.
   PubMed Web of Science ®Google Scholar
• Odden MC, Coxson PG, Moran A, et al. The impact of the aging population on coronary heart disease in the United States. Am J Med. 2011 Sept;124(9):827–33.e5.
   PubMed Web of Science ®Google Scholar
• Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007 June 7;356(23):2388–2398.
   PubMed Web of Science ®Google Scholar
• Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015 May 14;36(19):1163–1170.
   PubMed Web of Science ®Google Scholar
• Abu-Assi E, López-López A, González-Salvado V, et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed). 2016 Jan;69(1):11–18.
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with st-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267–315.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213–260.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015 May 7;372(19):1791–1800.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013 Oct;34(38):2949–3003.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 May 15;49(19):1982–1988.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12;366(15):1404–1413.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017 Oct 5;377(14):1319–1330.
   PubMed Web of Science ®Google Scholar
• Fox KAA, Eikelboom JW, Anand SS, et al. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Eur Heart J. 2019 May 7;40(18):1466–1471.
   PubMed Web of Science ®Google Scholar
• Shanker A, Bhupathi V. Secondary prevention with antithrombotic therapies in stable ischemic heart disease patients: a review. Curr Cardiol Rep. 2019 May 18;21(7):56.
   PubMed Web of Science ®Google Scholar
• Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants in the treatment of coronary and peripheral atherosclerosis. Kardiol Pol. 2019 Feb 18;77(4):490–504.
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Zannad F. Rivaroxaban: a new treatment paradigm in the setting of vascular protection? Thromb Haemost. 2018 May;118(S 01):S12–S22.
   PubMedGoogle Scholar
• Frangogianis NG. Pathophysiology of myocardial infarction. Compr Physiol. 2015 Sept 20;5(4):1841–1875.
   PubMed Web of Science ®Google Scholar
• Coppens M, Weitz JI, Eikelboom JWA. Synergy of dual pathway inhibition in chronic cardiovascular disease. Circ Res. 2019 Feb;124(3):416–425.
   PubMed Web of Science ®Google Scholar
• Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet–coagulation pathway interaction. In vitro and in vivo studies. J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):554–562.
   PubMed Web of Science ®Google Scholar
• Al Said S, Bode C, Duerschmied D. Anticoagulation in atherosclerotic disease. Hamostaseologie. 2018 Nov;38(4):240–246.
   PubMed Web of Science ®Google Scholar
• Niessner A, Agewall S. Critical appraisal of the COMPASS trial. Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):191–192.
   PubMed Web of Science ®Google Scholar
• Barrios V, Almendro-Delia M, Facila L, et al. Rivaroxaban: searching the integral vascular protection. Expert Rev Clin Pharmacol. 2018 July;11(7):719.
   PubMed Web of Science ®Google Scholar
• Patrono C. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. Cardiovasc Res. 2017 Dec 1;113(14):e61–e63.
   PubMed Web of Science ®Google Scholar
• Lim GB. Antithrombotic therapy: COMPASS points to low-dose rivaroxaban and aspirin for secondary prevention. Nat Rev Cardiol. 2017 Nov;14(11):630–631.
   PubMed Web of Science ®Google Scholar
• Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol. 2017 Aug;33(8):1027–1035.
   PubMed Web of Science ®Google Scholar
• Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018 June 12;137(24):2551–2553.
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002 Sept 26;347(13):969–974.
   PubMed Web of Science ®Google Scholar
• van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002 July 13;360(9327):109–113.
   PubMed Web of Science ®Google Scholar
• Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):62S–69S.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011 Nov;32(22):2781–2789.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sept 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669–676.
   PubMed Web of Science ®Google Scholar
• Dale B, Eikelboom JW, Weitz JI, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis. 2013 Feb;35(2):295–301.
   PubMed Web of Science ®Google Scholar
• Achilles A, Mohring A, Dannenberg L, et al. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation. J Thromb Haemost. 2017 Mar;15(3):473–476.
   PubMed Web of Science ®Google Scholar
• Borst O, Münzer P, Alnaggar N, et al. Inhibitory mechanisms of very low dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Adv. 2018 Mar 27;2(6):715–730.
   PubMed Web of Science ®Google Scholar
• Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, et al. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol. 2018 Feb;84(2):280–291.
   PubMed Web of Science ®Google Scholar
• Hara T, Fukuda D, Tanaka K, et al. Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire mediated vascular injury. Eur J Pharmacol. 2018 Feb 5;820:222–228.
   PubMed Web of Science ®Google Scholar
• Sanada F, Muratsu J, Otsu R, et al. Local production of activated factor X in atherosclerotic plaque induced vascular smooth muscle cell. Sci Rep. 2017 Dec 7;7(1):17172.
   PubMedGoogle Scholar
• Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015 Oct;242(2):639–646.
   PubMed Web of Science ®Google Scholar
• Wu TC, Chan JS, Lee CY, et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015 June 16;14:81.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25;365(8):699–708.
   PubMed Web of Science ®Google Scholar
• Petzold T, Thienel M, Dannenberg L, et al. Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res. 2020 Feb 14;126(4):486–500.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sharma A, Uchino K, et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013 Dec;24(8):628–635.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Jan 5;366(1):9–19.
   PubMed Web of Science ®Google Scholar
• Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017 May 6;389(10081):1799–1808.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205–218.
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):219–229.
   PubMed Web of Science ®Google Scholar
• Shroyer AL, Grover FL, Hattler B, et al. Onpump versus off-pump coronary artery bypass surgery. N Engl J Med. 2009 Nov 5;361(19):1827–1837.
   PubMed Web of Science ®Google Scholar
• PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2446–2454.
   PubMed Web of Science ®Google Scholar
• Lamy A, Eikelboom J, Sheth T, et al. Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. J Am Coll Cardiol. 2019 Jan 22;73(2):121–130.
   PubMed Web of Science ®Google Scholar
• Anand SS, Eikelboom JW, Dyal L, et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial. J Am Coll Cardiol. 2019 July 2;73(25):3271–3280.
   PubMed Web of Science ®Google Scholar
• Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018 Oct 4;379(14):1332–1342.
   PubMed Web of Science ®Google Scholar
• Branch KR, Probstfield JL, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease: the COMPASS trial. Circulation. 2019 Aug 13;140(7):529–537.
   PubMed Web of Science ®Google Scholar
• Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17;119(10):1363–1369.
   PubMed Web of Science ®Google Scholar
• Jun M, James MT, Manns BJ, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015 Feb 3;350:h246.
   PubMed Web of Science ®Google Scholar
• Fox KAA, Antman EM, Montalescot G, et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 study. J Am Coll Cardiol. 2007 June 12;49(23):2249–2255.
   PubMed Web of Science ®Google Scholar
• Fox KAA, Bassand J-P, Mehta SR, et al. on behalf of the OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non–ST-segment elevation acute coronary syndromes. Ann Intern Med.2007 Sept 4;147(5):304–310.
   PubMed Web of Science ®Google Scholar
• Fox KAA, Eikelboom JW, Shestakovska O, et al. Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction: from the COMPASS trial. J Am Coll Cardiol. 2019 May 14;73(18):2243–2250.
   PubMed Web of Science ®Google Scholar
• Sharma M, Hart RG, Connolly SJ, et al. Stroke outcomes in the COMPASS trial. Circulation. 2019 Feb 26;139(9):1134–1145.
   PubMed Web of Science ®Google Scholar
• Tangelder MJ, Nwachuku CE, Jaff M, et al. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. J Endovasc Ther. 2015 Apr;22(2):261–268.
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407–477.
   PubMed Web of Science ®Google Scholar
• Schiele F, Puymirat E, Ferrières J, et al. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: the COMPASS criteria applied to a post-MI population. Int J Cardiol. 2019 Mar 1;278:7–13.
   PubMed Web of Science ®Google Scholar
• Kerkar P, Bose D, Nishandar T, et al. A critical analysis of the COMPASS trial with respect to benefit-risk assessment using the numbers needed to treat: applicability and relevance in Indian patients with stable cardiovascular disease. Indian Heart J. 2018 Nov–Dec;70(6):911–914.
   PubMedGoogle Scholar
• Würtz M, Olesen KKW, Thim T, et al. External applicability of the COMPASS trial: the Western Denmark heart registry. Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):192–199.
   PubMed Web of Science ®Google Scholar
• Darmon A, Sorbets E, Ducrocq G, et al. Association of multiple enrichment criteria with ischemic and bleeding risk-s among COMPASS-eligible patients. J Am Coll Cardiol. 2019 July 2;73(25):3281–3291.
   PubMed Web of Science ®Google Scholar
• Kruger PC, Guzik TJ, Eikelboom JW. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland. Kardiol Pol. 2019 Aug 23;77(7–8):661–669.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397–1405.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957–967.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145–153.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Nelson AJ. Rivaroxaban with or without aspirin for the secondary prevention of cardiovascular disease: clinical implications of the COMPASS trial. Am J Cardiovasc Drugs. 2019 Aug;19(4):343–348.
   PubMed Web of Science ®Google Scholar
• Sanmartín M, Bellmunt S, Cosín-Sales J, et al. Role of rivaroxaban in the prevention of atherosclerotic events. Expert Rev Clin Pharmacol. 2019 Aug;12(8):771–780.
   PubMed Web of Science ®Google Scholar
• Bainey KR, Welsh RC, Connolly SJ, et al. Rivaroxaban plus aspirin versus aspirin alone in patients with prior percutaneous coronary intervention (COMPASS-PCI). Circulation. 2020 Apr 7;141(14):1141–1151.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Lamy A, Levy P, et al. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2019 Nov 28. [ Epub ahead of print]. DOI:10.1093/cvr/cvz278
   PubMed Web of Science ®Google Scholar
• Ademi Z, Zomer E, Tonkin A, et al. Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective. Int J Cardiol. 2018 Nov 1;270:54–59.
   PubMed Web of Science ®Google Scholar